164 citations,
April 2008 in “Cochrane library” Current treatments for alopecia show no significant long-term benefits.
41 citations,
September 2018 in “Australasian journal of dermatology” No systemic treatment for alopecia areata has strong evidence of effectiveness.
5 citations,
June 2022 in “Frontiers in immunology” Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
4 citations,
September 2011 in “Expert Review of Dermatology” Various treatments exist for alopecia areata, but none are completely satisfactory; choice depends on age, disease extent, and preference.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
Baricitinib is a new, effective treatment for advanced alopecia areata but is costly and has risks.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
10 citations,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
1 citations,
May 2017 in “InTech eBooks” The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
71 citations,
March 2009 in “Seminars in cutaneous medicine and surgery” Alopecia areata can cause unpredictable hair loss, and treatments like corticosteroids and minoxidil may help but have varying side effects.
38 citations,
January 2009 in “Journal of Cutaneous Medicine and Surgery” A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.
29 citations,
June 2013 in “Journal of the Saudi Society of Dermatology & Dermatologic Surgery” Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.
20 citations,
June 2019 in “Experimental Dermatology” The research suggests that autophagy-related genes might play a role in causing alopecia areata.
2 citations,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
2 citations,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
February 2024 in “International neuropsychiatric disease journal” Alopecia areata severely impacts quality of life, mental health, and work productivity.
October 2023 in “Dermatology practical & conceptual” Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
July 2023 in “The Egyptian Journal of Hospital Medicine ” The conclusion is that emotional support and a variety of treatments are important for alopecia areata, but more research is needed.
218 citations,
April 2012 in “British Journal of Dermatology” Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.
191 citations,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
54 citations,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
26 citations,
June 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Regenerative therapies show promise for treating vitiligo and alopecia areata.
18 citations,
January 2014 in “Postępy Dermatologii i Alergologii” Personalized treatment plans are important for people with alopecia areata.
12 citations,
August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.
11 citations,
May 2009 in “Actas Dermo-Sifiliográficas” Some treatments can help hair regrowth in alopecia areata, but none offer a cure, and effectiveness varies.
7 citations,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.